Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz (tofacitinib).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
20 April 2021 Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
4 July 2014 Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.
20 April 2021 Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
4 July 2014 Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.
20 April 2021 Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR.
4 July 2014 Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.